| Literature DB >> 28249849 |
Abdul Hadi Said1, Yook Chin Chia2,3.
Abstract
OBJECTIVES: Dyslipidaemia is one of the main risk factors for cardiovascular disease, the leading cause of death in Malaysia. This study assessed the awareness, knowledge and practice of lipid management among primary care physicians undergoing postgraduate training in Malaysia.Entities:
Keywords: awareness, knowledge and practice; primary care physician
Mesh:
Year: 2017 PMID: 28249849 PMCID: PMC5353319 DOI: 10.1136/bmjopen-2016-013573
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Flow chart of data collection. ATP, Advance in Primary Care Training Programme; DFM, Diploma in Family Medicine.
Sociodemographic data of respondents
| Respondents profile | n (%) |
|---|---|
| Gender (n=463) | |
| Male | 121 (26.1) |
| Female | 342 (73.9) |
| Median age in years (IQR) | 32 (4) |
| Ethnicity (n=460) | |
| Malay | 183 (39.8) |
| Chinese | 137 (29.8) |
| Indian | 125 (27.2) |
| Others | 15 (3.2) |
| Years of practice in primary care setting | |
| Median (IQR) | 4 (4) |
| Number of patients seen per day (n=466) | |
| <20 | 27 (5.8) |
| 21—40 | 173 (37.1) |
| 41—60 | 156 (33.5) |
| 61–80 | 70 (15.0) |
| 81–100 | 35 (7.5) |
| >100 | 5 (1.1) |
| Current working sector (n=461) | |
| Government clinic | 236 (50.8) |
| General practitioner | 127 (27.3) |
| Hospital | 102 (21.9) |
*One of the respondents has been working as a general practitioner for 36 years and is currently undergoing the Diploma in Family Medicine (DFM) programme, a recent online postgraduate programme offered by the national Academy of Family Medicine.
Awareness and use of lipid guidelines among respondents
| Awareness and use of lipid guidelines | n (%) |
|---|---|
| Awareness of Malaysian CPG on management of dyslipidaemia (n=465) | |
| Yes | 456 (98.1) |
| No | 9 (1.9) |
| Awareness of AHA guideline on treatment of blood cholesterol (n=463) | |
| Yes | 364 (78.6) |
| No | 99 (21.4) |
| Use any lipid guidelines. (n=460) | |
| Yes | 440 (95.6) |
| No | 20 (4.4) |
| Guidelines use (participants can choose more than one) (n=466) | |
| Malaysian CPG | 429 (92.1) |
| AHA guideline* | 87 (18.7) |
| ATP III guideline† revised 2008 | 11 (2.4) |
| NICE guideline‡ 2008 | 42 (9.0) |
| Others§ | 1 (0.2) |
*American Heart Association (AHA) guideline 2013 on the treatment of blood cholesterol to reduce Atherosclerotic Cardiovascular Disease (ASCVD) risk.
†Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 2008.
‡National Institute for Health and Clinical Excellence (NICE) guideline on lipid modification 2008.
§The participant did not specify the guideline used.
ATP, Advance in Primary Care Training Programme; CPG, Clinical Practice Guideline.
Knowledge on management of dyslipidaemia
| Questions/scenarios | n (%) |
|---|---|
|
65-year-old male with IHD Prescribe statin medication | 377 (81.6) |
|
50-year-old female with LDL of 5.4 mmol/L Prescribe statin medication | 396 (85.7) |
|
45-year-old male, with DM Prescribe statin medication | 250 (53.8) |
|
Madam L with high risk score based on the scenario given (Framingham 21.5%), AHA (12.6%) Prescribe statin medication | 348 (75.7) |
|
Mr K with low risk score based on the scenario given (Framingham 9.4%), AHA (4%) Not prescribe any lipid drug | 328 (71.1) |
|
Primary target for DM patients LDL | 436 (93.6) |
|
Value of LDL target for DM patients <2.6 mmol/L | 313 (71.8) |
|
Primary target for DM with concomitant IHD patients LDL | 436 (93.8) |
|
Value of LDL target for DM with concomitant IHD patients <1.8 mmol/L | 139 (31.9) |
|
Next step after achieved target Continue statin at similar dose | 308 (66.5) |
AHA, American Heart Association; DM, diabetes mellitus; HDL, high-density lipoprotein; IHD, ischaemic heart disease; LDL, low-density lipoprotein.
Figure 2Total cumulative knowledge score.
Association between knowledge score and sociodemographic profile
| Knowledge | |||
|---|---|---|---|
| Sociodemographic profile | Poor | Good | p Value |
| Gender | |||
| Male | 31 (25.6) | 90 (74.4) | |
| Female | 108 (31.6) | 234 (68.4) | 0.25 |
| Ethnicity | |||
| Malay | 45 (24.6) | 138 (75.4) | |
| Chinese | 42 (30.7) | 95 (69.3) | 0.14 |
| Indian | 46 (36.8) | 79 (63.2) | |
| Others | 5 (33.3) | 10 (66.7) | |
| Age (years) ±SD | 33.3±4.6 | 33.8±4.7 | 0.07 |
| Years of practice (years) ±SD | 4.6±4.1 | 5.2±4.3 | 0.09 |
| Working sectors | |||
| Government clinic | 71 (30.1) | 165 (69.9) | |
| General practitioners | 43 (33.9) | 84 (66.1) | 0.31 |
| Hospital | 25 (24.5) | 77 (75.5) | |
| Number of patients per day | |||
| <20 | 9 (33.3) | 18 (66.7) | |
| 21–40 | 46 (26.6) | 127 (73.4) | 0.18 |
| 41–60 | 43 (27.6) | 113 (72.4) | |
| 61–80 | 22 (31.4) | 48 (68.6) | |
| 81–100 | 17 (48.6) | 18 (51.4) | |
| >100 | 2 (40) | 3 (60) | |
| Awareness of Malaysian CPG | |||
| Yes | 130 (28.6) | 324 (71.4) | |
| No | 9 (81.8) | 2 (18.2) | <0.001 |
| Use of guideline | |||
| Yes | 122 (27.4) | 323 (72.6) | <0.001 |
| No | 17 (81.0) | 4 (19.0) | |
CPG, Clinical Practice Guideline.
Practice among respondents
| Questions | n (%) |
|---|---|
| 1. Investigations before initiating statin (can choose more than one) | |
| Aspartate aminotransferase (AST) | 344 (73.8) |
| Full blood count | 26 (5.6) |
| Renal profile (electrolyte, urea and creatinine) | 119 (25.5) |
| Fasting blood glucose | 113 (24.2) |
| | |
| Creatine kinase | 103 (22.1) |
| 2. If a patient on statin therapy developed unexplained severe muscle symptoms/fatigue. What will you do? | |
| 3. Additional drug after statin failed to achieve target (can choose more than one) | |
| Niacin | 40 (8.6) |
| Ezetimibe | 239 (51.3) |
| Gemfibrozil | 195 (41.8) |
| Fenofibrate | 204 (43.8) |
| Others | 3 (0.6) |
| 4. Do you use cardiovascular risk calculator to calculate cardiovascular risk before initiating statin? (n=463) | |
| Yes | 369 (79.7) |
| No | 94 (20.3) |
Bold indicates correct answer.